Non‐vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter

Background Non‐vitamin K oral anticoagulants (NOACs) have emerged as alternatives to vitamin K antagonists in select situations. For left atrial (LA) appendage thrombus in nonvalvular atrial fibrillation (AF) or flutter, guidelines recommend oral anticoagulation (OAC) for at least 3 weeks prior to r...

Full description

Saved in:
Bibliographic Details
Published in:Pacing and clinical electrophysiology 2019-09, Vol.42 (9), p.1183-1190
Main Authors: Hussain, Aliza, Katz, William E., Genuardi, Michael V., Bhonsale, Aditya, Jain, Sandeep K., Kancharla, Krishna, Saba, Samir, Shalaby, Alaa A., Voigt, Andrew H., Wang, Norman C.
Format: Article
Language:English
Subjects:
Antagonists
Anticoagulants
atrial fibrillation
atrial flutter
Blood clots
Cardiac arrhythmia
Echocardiography
Fibrillation
left atrial thrombus
oral anticoagulation
Thrombosis
Vitamin K
Warfarin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Non‐vitamin K oral anticoagulants (NOACs) have emerged as alternatives to vitamin K antagonists in select situations. For left atrial (LA) appendage thrombus in nonvalvular atrial fibrillation (AF) or flutter, guidelines recommend oral anticoagulation (OAC) for at least 3 weeks prior to reassessment. Data comparing NOACs to warfarin in this scenario are scarce. Methods A retrospective study identified subjects with nonvalvular AF or flutter who were: a) noted to have LA thrombus detected on transesophageal echocardiography (TEE), b) previously not receiving long‐term OAC; and c) evaluated for resolution of LA thrombus by follow‐up TEE between 3 weeks to less than 1 year of the initial TEE. Results The study included 45 subjects with mean age 63.2 years, 69% male, 78% white race/ethnicity, 42% paroxysmal, and mean CHA2DS2‐VASc score 3.4 ± 1.7. All LA thrombi were confined to the appendage. OAC received included apixaban (3), dabigatran (13), rivaroxaban (6), and warfarin (23), The median follow‐up time to repeat TEE was 67 (interquartile range, 49‐96) days. LA appendage thrombus resolution rates were 76% for the entire cohort, 77% for NOACs, and 74% for warfarin. In univariable logistic regression analysis, LA appendage thrombus resolution was similar for NOACs when compared to warfarin (odds ratio, 1.20; 95% confidence interval, 0.31‐4.69; P = .79). Conclusions In patients nonvalvular AF or flutter who were OAC naïve at the time of diagnosis with LA appendage thrombus, complete resolution was similar between NOACs and warfarin.
ISSN:0147-8389
1540-8159
DOI:10.1111/pace.13765